Breaking News Instant updates and real-time market news.

RMD

ResMed

$87.51

-1.17 (-1.32%)

, NFLX

Netflix

$227.58

7.12 (3.23%)

17:17
01/22/18
01/22
17:17
01/22/18
17:17

On The Fly: After Hours Movers

UP AFTER EARNINGS: ResMed (RMD), up 10.3%... Netflix (NFLX), up 9%... TD Ameritrade (AMTD), up 2%. ALSO HIGHER: Harvard Bioscience (HBIO), up 16.7% fater it agreed to acquire Data Sciences for $70M and gave fiscal 2018 guidance... Oneok (OKE), up 1.8% after it provided FY18 guidance... Adobe (ADBE), up 1.7% after it raised its Q1 and FY18 earnings guidance. LOWER: Adamas Pharmaceuticals (ADMS), down 6.2% after it filed to sell $85M in common stock... Stemline (STML), down 4.6% after it filed to sell 3.7M shares of common stock... Jamba (JMBA), down 1.6% after its 2.1M share Block Trade.

RMD

ResMed

$87.51

-1.17 (-1.32%)

NFLX

Netflix

$227.58

7.12 (3.23%)

AMTD

TD Ameritrade

$55.88

0.71 (1.29%)

HBIO

Harvard Bioscience

$3.90

-0.05 (-1.27%)

OKE

Oneok

$59.88

1.56 (2.67%)

ADBE

Adobe

$197.84

2.11 (1.08%)

ADMS

Adamas Pharmaceuticals

$40.79

2.6 (6.81%)

STML

Stemline

$14.25

0.7 (5.17%)

JMBA

Jamba

$9.14

-0.01 (-0.11%)

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 23

    Jan

  • 30

    Jan

  • 16

    Feb

  • 08

    May

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

RMD ResMed
$87.51

-1.17 (-1.32%)

12/12/17
BMOC
12/12/17
NO CHANGE
Target $82
BMOC
Market Perform
ResMed price target raised to $82 from $74 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on ResMed to $82 as part of her "2018 MedTech Outlook" report, saying the company is at the "beginning of a new product cycle for its masks, including the launch of its AirF it F20, AirFit N20, and AirTouch F20". These masks, the analyst contends, come with higher gross margins and should also be better received by patients because of their greater comfort. Wuensch also notes the management's focus on expenses, having reorganized the company into sleep, respiratory, and software-as-a-service to streamline infrastructure and improve communication. The analyst keeps her Market Perform rating on ResMed.
08/02/17
08/02/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Neutral from Buy at Citi with analyst Kate McShane citing yesterday's guide-down, the shares look "too expensive for investors to jump into the name nearer-term." 2. Burlington Stores (BURL) downgraded to Neutral from Outperform at Credit Suisse with analyst Christian Buss saying that although the fundamentals of the company remain healthy, he sees limited upside to valuation as the multiples stay elevated despite more moderate industry growth prospects. 3. Big 5 Sporting (BGFV) downgraded to Hold from Buy at Deutsche Bank with analyst Mike Baker saying he expected Big Five's sales gains following The Sports Authority liquidation would decelerate at some point, but he notes that "trends fell off faster and to a greater extent than we suspected." 4. Ultimate Software (ULTI) downgraded to Hold from Buy at Deutsche Bank with analyst Nandan Amladi calling the second quarter results "mixed" and prefers to move to the sidelines until growth returns to the mid-20s target and leverage returns to the model. 5. ResMed (RMD) was downgraded to Neutral from Buy at BofA/Merrill and to Neutral from Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/02/17
08/02/17
DOWNGRADE

Neutral
ResMed downgraded to Neutral at Credit Suisse
As previously reported, Credit Suisse analyst Saul Hadassin downgraded ResMed to Neutral from Outperform following the company's Q4 in line earnings. The analyst also lowered his price target on the shares to A$9.40 from A$9.70.
08/02/17
SBSH
08/02/17
UPGRADE
SBSH
Buy
ResMed upgraded to Buy from Neutral at Citi
Citi analyst Victor Windeyer upgraded ResMed to Buy with following the company's Q4 results. Credit Suisse and BofA/Merrill downgraded the shares this morning. The analyst believes supply bottlenecks have been removed and that the mask category can return to growth. He raised his price target for ResMed shares to A$10.50 from A$10.
NFLX Netflix
$227.58

7.12 (3.23%)

01/18/18
MSCO
01/18/18
NO CHANGE
Target $255
MSCO
Overweight
Netflix international net additions estimate raised at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne raised his 2018 international net additions estimate for Netflix to 16.9M subscribers, which he added may still prove conservative. To support this view, he cites Netflix's success in driving a more rapid rate of adoption in younger markets in 2017. Swinburne also raised his price target on Netflix shares to $255 from $235 and keeps an Overweight rating on the stock.
01/18/18
BUCK
01/18/18
NO CHANGE
Target $251
BUCK
Buy
Netflix price target raised to $251 from $235 at Buckingham
Buckingham analyst Matthew Harrigan raised his price target on Netflix to $251 from $235, stating that while his assumptions for the company's upcoming earnings report this Monday are largely in-line with consensus, there could be upside to international streaming additions in the quarter. He also raised his 2018 EPS estimate to $2.49 from $2.37 to account for a lower tax rate assumption. Harrigan keeps a Buy rating on Netflix shares.
01/19/18
KEYB
01/19/18
NO CHANGE
Target $270
KEYB
Overweight
Netflix price target raised to $270 from $230 at KeyBanc
KeyBanc analyst Andy Hargreaves raised his price target for Netflix to $270 saying the company's upcoming Q4 results "should remain solid." The streaming service closed yesterday up $2.83 to $220.33. The analyst raised his 2018 global net subscriber addition estimate to 20.6M from 19.3M citing sustained growth in the U.S. and an increase to his international total addressable market estimate. He sees potential for upside to subscriber estimates through 2018 and continues to recommend owning shares of Netflix with an Overweight rating. Netflix is the global leader in subscription video in the internet era, Hargreaves tells investors in a research note.
01/19/18
RSBL
01/19/18
NO CHANGE
Target $265
RSBL
Buy
Netflix price target raised to $265 from $225 at Rosenblatt
Rosenblatt analyst Alan Gould raised his price target on Netflix to $265 from $225 ahead of the company's Q4 earning report, noting that the company has beaten its overall subscriber guidance in 13 of the past 16 quarters. The company's guidance is for 6.3M net sub additions for the fourth quarter, which compares to the consensus forecast for 6.8M net sub additions, Gould noted. He maintains a Buy rating on Netflix shares.
AMTD TD Ameritrade
$55.88

0.71 (1.29%)

01/04/18
WELS
01/04/18
NO CHANGE
Target $67
WELS
Outperform
TD Ameritrade price target raised to $67 from $56 at Wells Fargo
Wells Fargo analyst Chris Harris raised his price target for TD Ameritrade to $67 from $56 to incorporate the benefits of tax reform as well as higher interest rates. The analyst reiterates an Outperform rating on the shares.
01/16/18
FBCO
01/16/18
NO CHANGE
Target $52
FBCO
Underperform
TD Ameritrade price target raised to $52 from $45 at Credit Suisse
Credit Suisse analyst Craig Siegenthaler raised his price target for TD Ameritrade to $52 from $45 ahead of quarterly results and to include the impacts of U.S. tax reform. The analyst reiterates an Underperform rating on the shares.
01/08/18
GSCO
01/08/18
NO CHANGE
GSCO
Goldman bullish on Brokers into 2018, upgrades Lazard and Stifel
Goldman Sachs analyst Conor Fitzgerald remains bullish on the Brokers and financial service companies heading into 2018. The analyst thinks large-cap mergers and acquisitions could accelerate and financial deals could return. To reflect these trends, Fitzgerald upgraded both Lazard (LAZ) and Stifel Financial (SF) to Buy from Neutral. The analyst prefers E-Trade (ETFC) and Charles Schwab (SCHW) over TD Ameritrade (AMTD) on the belief that commission price cuts are more likely than not in 2018. Further, Fitzgerald views Interactive Brokers' valuation as full and downgraded the shares to Sell from Neutral. Lastly, he sees a more balanced risk/reward for MarketAxess (MKTX) in this low volatility environment and downgraded the shares to Neutral from Buy.
01/08/18
LEHM
01/08/18
UPGRADE
Target $68
LEHM
Overweight
TD Ameritrade upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Jeremy Campbell upgraded TD Ameritrade to Overweight and raised his price target for the shares to $68 from $54. Commissions cuts over the next 12 months are a possibility rather than a likelihood, Campbell tells investors in a research note on the U.S. Brokers, Asset Managers & Exchanges sector. The analyst believes TD Ameritrade shares are attractively valued at current levels.
HBIO Harvard Bioscience
$3.90

-0.05 (-1.27%)

OKE Oneok
$59.88

1.56 (2.67%)

01/16/18
RBCM
01/16/18
UPGRADE
RBCM
Outperform
Oneok upgraded to Outperform from Sector Perform at RBC Capital
01/16/18
RBCM
01/16/18
UPGRADE
Target $68
RBCM
Outperform
Oneok upgraded to Outperform at RBC Capital on Williston Basin exposure
As reported earlier, RBC Capital analyst Elvira Scotto upgraded Oneok to Outperform from Sector Perform and raised her price target to $68 from $57. Scotto cites an "attractive asset footprint", particularly in the Williston Basin, as well as the company's mainly "fee-based cash flow". The analyst expects Oneok to generate EBITDA growth of about 40% from 2017 to 2020 with "minimal to no equity needs".
01/17/18
LEHM
01/17/18
UPGRADE
Target $67
LEHM
Overweight
Oneok upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Christine Cho upgraded Oneok to Overweight and raised her price target for the shares to $67 from $58. The analyst realigned her ratings in the space to favor commodity and volume exposure.
01/11/18
WELS
01/11/18
UPGRADE
Target $66
WELS
Outperform
Oneok upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Michael Blum upgraded Oneok to Outperform and raised his price target for the shares to $66 from $58. The company's "dominant position" in the Bakken and mid-continent should enable it to continue to grow the dividend at a three-year annual rate of 8.6%, Blum tells investors in a research note.
ADBE Adobe
$197.84

2.11 (1.08%)

12/15/17
JEFF
12/15/17
NO CHANGE
Target $205
JEFF
Buy
Adobe price target raised to $205 from $190 at Jefferies
Jefferies analyst Brent Thill raised his price target for Adobe Systems to $205 saying the company has momentum into fiscal 2018 following last night's Q4 beat. Even fiscal 2019 looks good as the company will benefit from price increases rolling out in March 2018, Thill tells investors in a post-earnings research note. He keeps a Buy rating on Adobe.
12/15/17
BMOC
12/15/17
NO CHANGE
Target $205
BMOC
Outperform
Adobe price target raised to $205 from $187 at BMO Capital
BMO Capital analyst Keith Bachman raised his price target on Adobe to $205 after yesterday's Q4 earnings beat. Bachman says he remains positive on the company's fundamentals after it generated "significant upside" in margins and EPS. The analyst adds that FY18 operating margin guidance is likely to prove conservative as it implies 240bps expansion after 420bps expansion in FY17 and 350bos expansion in Q4. Bachman keeps his Outperform rating on Adobe.
12/15/17
JMPS
12/15/17
NO CHANGE
Target $210
JMPS
Outperform
Adobe price target raised to $210 from $170 at JMP Securities
JMP Securities analyst Patrick Walravens increased his price target on Adobe to $210 from $170 after the company reported results he called "strong" and raised its FY18 revenue guidance. The company's 25% revenue growth in Q4 with a 40% non-GAAP operating margin demonstrates the power of its core franchises, said Walravens, who keeps an Outperform rating on the shares.
01/18/18
KEYB
01/18/18
NO CHANGE
KEYB
Cost savings emerge as 'killer app' for artificial intelligence, says KeyBanc
Over the past 35 days, KeyBanc analyst Brent Bracelin hosted meetings at Adobe (ADBE), Autodesk (ADSK), Algorithmia, Cloudera (CLDR), Coupa (COUP), Facebook (FB), Guidewire (GWRE), Netflix (NFLX), NVIDIA (NVDA), Salesforce (CRM), SAP, Synopsys (SNPS), Twilio (TWLO), Tableau (DATA), Talend (TLND), Veeva (VEEV), Workday (WDAY), and Zendesk (ZEN) as part of an AI & Cloud-themed field trip. The analyst notes that cost savings have emerged as the "killer app" for artificial intelligence, and large enterprise interest in migrating back-office apps to cloud has been slow, but is picking up, conversational AI and bot activity is yielding real cost savings. Further, Bracelin sees 2018 as a defining year for enterprise AI applications, and is most impressed by enterprise AI initiatives at Microsoft (MSFT), Zendesk, Guidewire, and Adobe.
ADMS Adamas Pharmaceuticals
$40.79

2.6 (6.81%)

10/30/17
10/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sotheby's (BID) initiated with a Buy at Aegis. 2. Alnylam (ALNY) initiated with a Buy at FBR Capital. 3. Adamas Pharmaceuticals (ADMS) initiated with an Outperform at Evercore ISI. 4. Vipshop (VIPS) initiated with a Neutral at UBS. 5. Rhythm Pharmaceuticals (RYTM) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/29/17
NORL
11/29/17
INITIATION
Target $70
NORL
Outperform
Adamas Pharmaceuticals initiated with an Outperform at Northland
Northland analyst Carl Byrnes initiated Adamas Pharmaceuticals with an Outperform and $70 price target. The analyst said Adamas' GOCOVRI is a breakthrough in treating Parkinson's patients that have developed dyskinesia as a result of long-term exposure to levodopa therapy and sees peak sales exceeding $750M.
12/13/17
COWN
12/13/17
NO CHANGE
Target $55
COWN
Outperform
Adamas Pharmaceuticals named a best idea for 2018 at Cowen
Cowen analyst Ken Cacciatore views shares of Adamas Pharmaceuticals as "meaningfully undervalued" at current levels. He calls the stock a best idea for 2018 and keeps an Outperform rating on the name with a $55 price target. The analyst is confident that Gocovri, which is now on the market, will find a "significant place" in the Parkinson's disease treatment paradigm. He says Adamas has successfully developed an extended release amantadine for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease.
12/19/17
PIPR
12/19/17
NO CHANGE
Target $52
PIPR
Overweight
Adamas Pharmaceuticals price target raised to $52 from $35 at Piper Jaffray
Piper Jaffray analyst David Amsellem raised his price target for Adamas Pharmaceuticals to $52 saying his survey of 27 neurologists who treat a significant number of patients with epilepsy yielded "encouraging early feedback" on ADS-4101. The feedback suggests a relatively high degree of enthusiasm for a next-generation form of lacosamide, Amsellem tells investors in a research note. He views ADS-4101 as a "relatively underappreciated longer-term value driver" for Adamas and keeps an Overweight rating on the shares.
STML Stemline
$14.25

0.7 (5.17%)

02/03/17
JEFF
02/03/17
NO CHANGE
Target $16
JEFF
Buy
Jefferies more worried about Stemline management than approval
Jefferies analyst Biren Amin sees only small risk of a clinical hold and believes approval chances are favorable for Stemline Therapeutics' SL-401 after the company confirmed a patient death due to capillary leak syndrome. The analyst is cautious, however, on the ability of the company's management to regain investor confidence given the timing of the death relative to its recent financing. The lack of disclosure highlights the inability of management to make decisions with shareholders in mind, Amin tells investors in a research note. He points out that as of 8 PM EST last night, Stemline has not returned his calls. The analyst believes the most meaningful upside to the stock would be remedies to regain investor confidence. With that in mind, he advises the company to host an investor call. To reflect increased risk, Amin cut his price target for Stemline shares to $16 from $23. The stock closed yesterday down 43%, or $4.15, to $5.60. The analyst keeps a Buy rating on the name.
02/27/17
HCWC
02/27/17
NO CHANGE
Target $34
HCWC
Buy
Stemline clinical hold unlikely on lead candidate, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju believes a death due to capillary leak syndrome is unlikely to lead to a clinical hold on SL-401, Stemline Therapeutics' lead candidate in blastic plasmacytoid dendritic cell neoplasm, a rare blood cancer. The FDA is unlikely to place a clinical hold on the ongoing trial, since capillary leak syndrome is a known safety risk with SL-401 and given the fact that the only agent in this class to receive regulatory approval, Ontak, is also associated with this side-effect, Selvaraju tells investors in a research note. He reiterates a Buy rating on Stemline with a $34 price target. The stock closed Friday up 40c to $6.85.
03/20/17
LTCO
03/20/17
NO CHANGE
Target $41
LTCO
Buy
Stemline selloff creates buying opportunity, says Ladenburg
Ladenburg Thalmann analyst Matt Kaplan recommends using Friday's weakness in shares of Stemline Therapeutics as a buying opportunity. Following the disclosure of a death, the analyst tells investors that Stemline's patients are complicated with systemic disease impacting multiple organs. It is not uncommon to observe increased rates of cardiovascular issues including pericardial effusion and stroke in these patients, Kaplan tells investors in a research note. The data continue to "strongly support" the approval of SL-401 if the efficacy for the new cohort of patients is consistent with the prior data, the analyst contends. He reiterates a Buy rating on Stemline with a $41 price target.
06/14/17
COWN
06/14/17
NO CHANGE
COWN
Outperform
Stemline significant upside to shares at current valuation, says Cowen
Cowen analyst Boris Peaker said he sees significant upside for Stemline shares from current levels as he believes the company has a real drug for a highly unmet medical need in an orphan oncology indication, namely blastic plasmacytoid dendritic cell neoplasm. Although there are safety concerns, he believes there is a high chance of FDA approval and commercial uptake. Peaker called Stemline a best small/mid-cap idea and reiterated his Outperform rating on the shares.
JMBA Jamba
$9.14

-0.01 (-0.11%)

TODAY'S FREE FLY STORIES

OPTN

Optinose

$12.86

-6.64 (-34.05%)

15:28
08/14/18
08/14
15:28
08/14/18
15:28
Recommendations
Optinose analyst commentary  »

Piper not worried by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

BOOT

Boot Barn

$27.93

1.04 (3.87%)

15:20
08/14/18
08/14
15:20
08/14/18
15:20
Options
Sweep call buyers in Boot Barn as shares lift on heavy volume »

Sweep call buyers in Boot…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

CREE

Cree

$49.94

-0.34 (-0.68%)

15:19
08/14/18
08/14
15:19
08/14/18
15:19
Options
Cree options imply 15.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
08/14/18
08/14
15:17
08/14/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
08/14/18
08/14
15:16
08/14/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSBR

Champions Oncology

$7.80

0.315 (4.21%)

15:12
08/14/18
08/14
15:12
08/14/18
15:12
Conference/Events
Champions Oncology management to meet with Craig-Hallum »

.Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 15

    Aug

GLF

GulfMark Offshore

$38.18

0.48 (1.27%)

15:10
08/14/18
08/14
15:10
08/14/18
15:10
Hot Stocks
Breaking Hot Stocks news story on GulfMark Offshore »

GulfMark Offshore Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$284.02

1.89 (0.67%)

15:06
08/14/18
08/14
15:06
08/14/18
15:06
Technical Analysis
Technical Take: SPDR S&P 500 ETF near session highs in final hour of trading »

The SPDR S&P 500 ETF…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$284.02

1.89 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

A

Agilent

$67.01

1.06 (1.61%)

15:04
08/14/18
08/14
15:04
08/14/18
15:04
Options
Agilent options imply 9.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 19

    Aug

  • 21

    Aug

CLF

Cleveland-Cliffs

$9.97

-0.235 (-2.30%)

15:00
08/14/18
08/14
15:00
08/14/18
15:00
Options
15K Cleveland Cliffs Aug - Oct 8 call spreads bought for 17c »

15K Cleveland Cliffs Aug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

15:00
08/14/18
08/14
15:00
08/14/18
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

WMT

Walmart

$90.90

1.24 (1.38%)

14:59
08/14/18
08/14
14:59
08/14/18
14:59
Hot Stocks
Walmart opens distribution center in Mobile, Alabama »

Walmart commemorated the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

SPR

Spirit AeroSystems

$86.53

-0.23 (-0.27%)

14:57
08/14/18
08/14
14:57
08/14/18
14:57
Hot Stocks
Spirit AeroSystems VP Michelle Lohmeier sells almost $300K in company stock »

Spirit AeroSystems VP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPOT

Spotify

$193.85

2.4 (1.25%)

, UXIN

Uxin

$5.54

-0.61 (-9.92%)

14:57
08/14/18
08/14
14:57
08/14/18
14:57
Hot Stocks
Tiger Global adds Spotify and Adobe, exits United Continental »

Chase Coleman's…

SPOT

Spotify

$193.85

2.4 (1.25%)

UXIN

Uxin

$5.54

-0.61 (-9.92%)

COUP

Coupa Software

$67.20

1.66 (2.53%)

ADBE

Adobe

$255.81

2.23 (0.88%)

GDS

GDS Holdings

$30.05

-2.58 (-7.91%)

EHIC

eHi Car Services

$12.90

0.05 (0.39%)

ARCC

Ares Capital

$17.37

0.015 (0.09%)

UAL

United Continental

$81.84

0.58 (0.71%)

TWTR

Twitter

$33.04

0.24 (0.73%)

FB

Facebook

$180.91

0.83 (0.46%)

NOW

ServiceNow

$184.66

-0.38 (-0.21%)

MLI

Mueller Industries

$31.95

0.18 (0.57%)

RUN

Sunrun

$12.99

-0.22 (-1.67%)

RDFN

Redfin

$18.04

-0.5 (-2.70%)

JD

JD.com

$33.55

-1.51 (-4.31%)

TDG

TransDigm

$355.86

-0.2 (-0.06%)

MSFT

Microsoft

$109.51

1.27 (1.17%)

AMZN

Amazon.com

$1,915.47

19.96 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 16

    Aug

  • 16

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 28

    Aug

  • 04

    Sep

  • 04

    Sep

  • 06

    Sep

  • 07

    Sep

  • 12

    Sep

  • 12

    Sep

  • 13

    Sep

  • 18

    Sep

DENN

Denny's

$14.66

0.12 (0.83%)

14:53
08/14/18
08/14
14:53
08/14/18
14:53
Conference/Events
Denny's participates in a conference call with Stephens »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 16

    Aug

  • 06

    Nov

WPM

Wheaton Precious Metals

$19.94

-0.1 (-0.50%)

14:49
08/14/18
08/14
14:49
08/14/18
14:49
Options
Wheaton Precious Metals options imply 5.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

DWSN

Dawson Geophysical

$5.90

0.04 (0.68%)

14:48
08/14/18
08/14
14:48
08/14/18
14:48
Hot Stocks
Dawson Geophysical director William Barrett buys over $100K in stock »

Dawson Geophysical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$180.92

0.84 (0.47%)

, GOOG

Alphabet

$1,242.00

6.9 (0.56%)

14:48
08/14/18
08/14
14:48
08/14/18
14:48
Conference/Events
William Blair digital media analyst to hold a meeting »

Analysts, along with the…

FB

Facebook

$180.92

0.84 (0.47%)

GOOG

Alphabet

$1,242.00

6.9 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 22

    Aug

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

14:46
08/14/18
08/14
14:46
08/14/18
14:46
Conference/Events
William Blair SaaS analyst to hold a group luncheon »

Software as a Service…

GLF

GulfMark Offshore

$38.18

0.48 (1.27%)

14:45
08/14/18
08/14
14:45
08/14/18
14:45
Hot Stocks
Breaking Hot Stocks news story on GulfMark Offshore »

GulfMark Offshore Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KR

Kroger

$30.38

0.63 (2.12%)

, BABA

Alibaba

$171.94

-5.715 (-3.22%)

14:44
08/14/18
08/14
14:44
08/14/18
14:44
Hot Stocks
Kroger announces pilot for sales in China via Alibaba's Tmall platform »

Kroger (KR) announced a…

KR

Kroger

$30.38

0.63 (2.12%)

BABA

Alibaba

$171.94

-5.715 (-3.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 10

    Sep

14:43
08/14/18
08/14
14:43
08/14/18
14:43
Conference/Events
Stephens retail/hardlines analyst to hold luncheon meeting »

Retail/Hardlines Analyst…

TWTR

Twitter

$33.03

0.23 (0.70%)

14:43
08/14/18
08/14
14:43
08/14/18
14:43
Hot Stocks
Twitter suspends accounts for trying to evade account suspension »

Twitter's Safety…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

PLNT

Planet Fitness

$51.74

2.75 (5.61%)

14:40
08/14/18
08/14
14:40
08/14/18
14:40
Options
Bullish flow in Planet Fitness as shares rebound »

Bullish flow in Planet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$87.59

0.56 (0.64%)

14:30
08/14/18
08/14
14:30
08/14/18
14:30
Options
Bullish option play opened in Paypal »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 15

    Aug

  • 16

    Aug

  • 12

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.